Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Appointment of President
On May 14, 2021, the Board of Directors (the "Board") of Rain Therapeutics Inc.
(the "Company") approved the recommendation of Avanish Vellanki, the Company's
Chief Executive Officer and Chairman of the Board, to appoint Robert Doebele,
M.D., Ph.D. to the position of President, effective as of such date. Dr. Doebele
will continue to serve as the Company's Chief Scientific Officer. Mr. Vellanki,
who previously held the title of President, ceased serving as President upon Dr.
Doebele's appointment.
CEO Compensation
On May 14, 2021, the Board also approved the recommendations of the Compensation
Committee of the Board of a 2021 annual base salary and 2021 bonus target for
Mr. Vellanki of $562,200 and 50%, respectively. The salary change is retroactive
to April 26, 2021.
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses